A Theoretical Comparison of No-U-Turn Sampler Variants: Necessary and Su?cient Convergence Conditions and Mixing Time Analysis under Gaussian Targets
New mathematical proof shows one variant of the core Bayesian sampling algorithm converges faster.
A team of five researchers has published a significant theoretical paper that finally provides rigorous mathematical guarantees for the two main variants of the No-U-Turn Sampler (NUTS). NUTS is the default Markov Chain Monte Carlo (MCMC) algorithm in major probabilistic programming libraries like PyMC, NumPyro, and Stan, used by thousands of data scientists for Bayesian inference. The paper, "A Theoretical Comparison of No-U-Turn Sampler Variants," tackles a long-standing gap by establishing the first necessary conditions for geometric ergodicity for both the NUTS-mul (multinomial sampling) and NUTS-BPS (biased progressive sampling) variants, and the first sufficient conditions for NUTS-mul.
The core finding is that while both algorithms exhibit nearly identical qualitative behavior—their convergence depends on the target distribution's tail properties—they differ quantitatively in speed. For a standard d-dimensional Gaussian target, the mixing time for both scales as O(d^{1/4}), but the constants are strictly smaller for NUTS-BPS. This translates to NUTS-BPS having a faster convergence rate in practice, potentially offering a 15-20% performance improvement for complex, high-dimensional models. This work provides a solid mathematical foundation for algorithm selection and future optimizations in probabilistic computing.
- Establishes first necessary conditions for geometric ergodicity for both NUTS-mul and NUTS-BPS variants.
- Proves mixing times for both scale as O(d^{1/4}) on Gaussian targets, but NUTS-BPS has smaller constants.
- Provides theoretical justification for preferring NUTS-BPS in high-dimensional Bayesian inference tasks for faster convergence.
Why It Matters
This work provides the mathematical backbone for faster, more reliable Bayesian inference in fields from drug discovery to finance.